These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11991013)

  • 1. Substandard and counterfeit drugs in developing countries.
    Behrens RH; Awad AI; Taylor RB
    Trop Doct; 2002 Jan; 32(1):1-2. PubMed ID: 11991013
    [No Abstract]   [Full Text] [Related]  

  • 2. Spurious and counterfeit drugs: a growing industry in the developing world.
    Gautam CS; Utreja A; Singal GL
    Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viewpoint: Counterfeit medicines and substandard medicines: Different problems requiring different solutions.
    't Hoen E; Pascual F
    J Public Health Policy; 2015 Nov; 36(4):384-9. PubMed ID: 26178809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substandard and counterfeit antimicrobials: recent trends and implications to key public health interventions in developing countries.
    Tadeg H; Berhane Y
    East Afr J Public Health; 2012 Jun; 9(2):85-9. PubMed ID: 23139963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substandard and counterfeit medicines.
    Rassool GH
    J Adv Nurs; 2004 May; 46(3):338-9. PubMed ID: 15119344
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of substandard drugs in developing countries.
    Afu S
    Trop Med Int Health; 1999 Jan; 4(1):73. PubMed ID: 10203177
    [No Abstract]   [Full Text] [Related]  

  • 7. Counterfeit anti-infective drugs.
    Newton PN; Green MD; Fernández FM; Day NP; White NJ
    Lancet Infect Dis; 2006 Sep; 6(9):602-13. PubMed ID: 16931411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment.
    Mackey TK; Liang BA; York P; Kubic T
    Am J Trop Med Hyg; 2015 Jun; 92(6 Suppl):59-67. PubMed ID: 25897059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Counterfeit drugs in Israel and worldwide. Part II: distribution profile and anti-counterfeiting strategies and actions].
    Furman-Assaf S; Tamir O; Marom E; Arieli M; Shemer J
    Harefuah; 2010 Jul; 149(7):470-5, 479. PubMed ID: 21465764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quality of medicines in least developed countries].
    Videau JY
    Med Trop (Mars); 2006 Dec; 66(6):533-7. PubMed ID: 17286015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does price reveal poor-quality drugs? Evidence from 17 countries.
    Bate R; Jin GZ; Mathur A
    J Health Econ; 2011 Dec; 30(6):1150-63. PubMed ID: 21917346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Counterfeit drugs in Israel and worldwide. Part I: the extent of occurrence and impending threats].
    Tamir O; Friedman N; Furman-Assaf S; Marom E; Arieli M; Shemer J
    Harefuah; 2010 Jul; 149(7):466-9, 479. PubMed ID: 21465763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canada delays legislation on cheap drugs.
    Kondro W
    Lancet; 2003 Nov; 362(9397):1729. PubMed ID: 14655664
    [No Abstract]   [Full Text] [Related]  

  • 14. Counterfeit and substandard drugs in India may be smaller problem than claimed, say government findings.
    Travasso C
    BMJ; 2014 Jan; 348():g60. PubMed ID: 25489932
    [No Abstract]   [Full Text] [Related]  

  • 15. Counterfeit drugs lawsuit points finger at wholesaler, pharmacy.
    Young D
    Am J Health Syst Pharm; 2004 Oct; 61(19):1978, 1980, 1984. PubMed ID: 15509115
    [No Abstract]   [Full Text] [Related]  

  • 16. Access to essential drugs in poor countries: a lost battle?
    Pécoul B; Chirac P; Trouiller P; Pinel J
    JAMA; 1999 Jan; 281(4):361-7. PubMed ID: 9929090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 1999; 885():i-vi, 1-156. PubMed ID: 10352573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Legal Uncertainty-The Gray Area around Substandard Medicines: Where Public Health Meets Law.
    Olliaro E; Olliaro P; Ho CWL; Ravinetto R
    Am J Trop Med Hyg; 2020 Feb; 102(2):262-267. PubMed ID: 31746313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of poor-quality medicines in the 'developing' world.
    Newton PN; Green MD; Fernández FM
    Trends Pharmacol Sci; 2010 Mar; 31(3):99-101. PubMed ID: 20117849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substandard drugs: a potential crisis for public health.
    Johnston A; Holt DW
    Br J Clin Pharmacol; 2014 Aug; 78(2):218-43. PubMed ID: 24286459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.